Direct renin inhibition: an evaluation of the safety and tolerability of aliskiren

References

• Atlas SA. The renin-angiotensin-aldosterone system: pathophysiological role and pharmacologic inhibition. J Manag Care Pharm 2007;13(Suppl B):9–201Atlas SA. The renin-angiotensin-aldosterone system: pathophysiological role and pharmacologic inhibition. J Manag Care Pharm 2007;13(Suppl B):9–20
   PubMedGoogle Scholar
• Gradman AH, Schmieder RE, Lins RL. et al. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 2005;111:1012–182Gradman AH, Schmieder RE, Lins RL. et al. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 2005;111:1012–18
   PubMed Web of Science ®Google Scholar
• Oh B-H, Mitchell J, Herron JR. et al. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J Am Coll Cardiol 2007;49:1157–633Oh B-H, Mitchell J, Herron JR. et al. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J Am Coll Cardiol 2007;49:1157–63
   PubMed Web of Science ®Google Scholar
• Stanton A, Jensen C, Nussberger J. et al. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension 2003;42:1137–434Stanton A, Jensen C, Nussberger J. et al. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension 2003;42:1137–43
   PubMed Web of Science ®Google Scholar
• Strasser RH, Puig JG, Farsang C. et al. A comparison of the tolerability of the direct renin inhibitor aliskiren and lisinopril in patients with severe hypertension. J Hum Hypertens 2007; 21:780–75Strasser RH, Puig JG, Farsang C. et al. A comparison of the tolerability of the direct renin inhibitor aliskiren and lisinopril in patients with severe hypertension. J Hum Hypertens 2007; 21:780–7
   PubMed Web of Science ®Google Scholar
• Uresin Y, Taylor AA, Kilo C. et al. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. J Renin Angiotensin Aldosterone Syst 2007;8:190–86Uresin Y, Taylor AA, Kilo C. et al. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. J Renin Angiotensin Aldosterone Syst 2007;8:190–8
   PubMed Web of Science ®Google Scholar
• Pool JL, Schmieder RE, Azizi M. et al. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am J Hypertens 2007; 20:11–207Pool JL, Schmieder RE, Azizi M. et al. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am J Hypertens 2007; 20:11–20
   PubMed Web of Science ®Google Scholar
• Oparil S, Yarows SA, Patel S. et al. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet 2007; 370:221–98Oparil S, Yarows SA, Patel S. et al. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet 2007; 370:221–9
   PubMed Web of Science ®Google Scholar
• Villamil A, Chrysant SG, Calhoun D. et al. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens 2007; 25:217–269Villamil A, Chrysant SG, Calhoun D. et al. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens 2007; 25:217–26
   PubMed Web of Science ®Google Scholar
• Jordan J, Engeli S, Boye SW. et al. Direct renin inhibition with aliskiren in obese patients with arterial hypertension. Hypertension 2007;49:1047–5510Jordan J, Engeli S, Boye SW. et al. Direct renin inhibition with aliskiren in obese patients with arterial hypertension. Hypertension 2007;49:1047–55
   PubMed Web of Science ®Google Scholar
• Drummond W, Munger MA, Rafique EM. et al. Antihypertensive efficacy of the oral direct renin inhibitor aliskiren as add-on therapy in patients not responding to amlodipine monotherapy. J Clin Hypertens (Greenwich) 2007;9:742–5011Drummond W, Munger MA, Rafique EM. et al. Antihypertensive efficacy of the oral direct renin inhibitor aliskiren as add-on therapy in patients not responding to amlodipine monotherapy. J Clin Hypertens (Greenwich) 2007;9:742–50
   PubMedGoogle Scholar
• Tekturna® (aliskiren) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; March 2007.12Tekturna® (aliskiren) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; March 2007.
   Google Scholar
• Vaidyanathan S, Reynolds C, Yeh C-M, et al. Pharmacokinetics, safety, and tolerability of the novel oral direct renin inhibitor aliskiren in elderly healthy subjects. J Clin Pharmacol 2007; 47:453–6013Vaidyanathan S, Reynolds C, Yeh C-M, et al. Pharmacokinetics, safety, and tolerability of the novel oral direct renin inhibitor aliskiren in elderly healthy subjects. J Clin Pharmacol 2007; 47:453–60
   PubMed Web of Science ®Google Scholar
• Shafiq MM, Menon DV, Victor RG. Oral direct renin inhibition: premise, promise, and potential limitations of a new antihypertensive drug. Am J Med 2008;121:265–7114Shafiq MM, Menon DV, Victor RG. Oral direct renin inhibition: premise, promise, and potential limitations of a new antihypertensive drug. Am J Med 2008;121:265–71
   PubMed Web of Science ®Google Scholar
• Palmer BF. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med 2004; 351:585–9215Palmer BF. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med 2004; 351:585–92
   PubMed Web of Science ®Google Scholar
• Parfrey PS. Inhibitors of the renin-angiotensin system: proven benefits, unproven safety. Ann Intern Med. 2008;148:74–7716Parfrey PS. Inhibitors of the renin-angiotensin system: proven benefits, unproven safety. Ann Intern Med. 2008;148:74–77
   Google Scholar
• The PEACE Trial InvestigatorsAngiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004; 351:2058–6817The PEACE Trial InvestigatorsAngiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004; 351:2058–68
   PubMed Web of Science ®Google Scholar
• Ruggenenti P, Fassi A, Ilieva AP. et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004;351:1941–5118Ruggenenti P, Fassi A, Ilieva AP. et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004;351:1941–51
   PubMed Web of Science ®Google Scholar
• Karlberg BE. Cough and inhibition of the renin-angiotensin system. J Hypertens Suppl 1993;11:49–5219Karlberg BE. Cough and inhibition of the renin-angiotensin system. J Hypertens Suppl 1993;11:49–52
   Google Scholar
• Weir MR, Bush C, Anderson DR. et al. Antihypertensive efficacy, safety and tolerability of the oral renin inhibitor aliskiren in patients with hypertension: a pooled analysis. J Am Soc Hypertens 2007;1:264–7720Weir MR, Bush C, Anderson DR. et al. Antihypertensive efficacy, safety and tolerability of the oral renin inhibitor aliskiren in patients with hypertension: a pooled analysis. J Am Soc Hypertens 2007;1:264–77
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Title 21 – food and drugs chapter 1 – Food and Drug Administration Department of Health and Human Services Subchapter D – drugs for human use. Available from .21US Food and Drug Administration. Title 21 – food and drugs chapter 1 – Food and Drug Administration Department of Health and Human Services Subchapter D – drugs for human use. Available from.
   Google Scholar
• Schmieder RE, Philipp T, Guerediaga J, et al. Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazide. Circulation. In Press.22Schmieder RE, Philipp T, Guerediaga J, et al. Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazide. Circulation. In Press.
   Web of Science ®Google Scholar
• Gradman AH, Kolloch RE, Meyers M. et al. Aliskiren in combination with hydrochlorothiazide is effective and well tolerated during long-term treatment of hypertension [abstract]. J Clin Hypertens 2007;9(Suppl A5):A16023Gradman AH, Kolloch RE, Meyers M. et al. Aliskiren in combination with hydrochlorothiazide is effective and well tolerated during long-term treatment of hypertension [abstract]. J Clin Hypertens 2007;9(Suppl A5):A160
   Google Scholar
• Tekturna HCT [prescribing information]. East Hanover, NJ: Novartis Pharmaceutical Corporation; January 2008.24Tekturna HCT [prescribing information]. East Hanover, NJ: Novartis Pharmaceutical Corporation; January 2008.
   Google Scholar
• Vaidyanathan S, Valencia J, Kemp C. et al. Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers. Int J Clin Pract 2006;60:1343–5625Vaidyanathan S, Valencia J, Kemp C. et al. Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers. Int J Clin Pract 2006;60:1343–56
   PubMed Web of Science ®Google Scholar
• Zhao C, Vaidyanathan S, Dieterich HA. et al. Assessment of the pharmacokinetic interaction between the oral direct renin inhibitor aliskiren and furosemide: a study in healthy volunteers [abstract]. Clin Pharmacol Ther 2007;81(Suppl 1):S11026Zhao C, Vaidyanathan S, Dieterich HA. et al. Assessment of the pharmacokinetic interaction between the oral direct renin inhibitor aliskiren and furosemide: a study in healthy volunteers [abstract]. Clin Pharmacol Ther 2007;81(Suppl 1):S110
   Google Scholar
• Dieterich HA, Warren V, Sabo R. et al. Lack of pharmacokinetic interaction between the oral direct renin inhibitor aliskiren and pioglitazone or fenofibrate in healthy volunteers [abstract]. Basic Clin Pharmacol Toxicol 2007;101:135–627Dieterich HA, Warren V, Sabo R. et al. Lack of pharmacokinetic interaction between the oral direct renin inhibitor aliskiren and pioglitazone or fenofibrate in healthy volunteers [abstract]. Basic Clin Pharmacol Toxicol 2007;101:135–6
   Google Scholar
• Reynolds C, Vaidyanathan S, Dieterich HA. et al. Assessment of pharmacokinetic interaction between aliskiren, a novel direct renin inhibitor, and metformin in healthy volunteers [abstract]. Clin Pharmacol Ther 2006;81(Suppl 1):S11028Reynolds C, Vaidyanathan S, Dieterich HA. et al. Assessment of pharmacokinetic interaction between aliskiren, a novel direct renin inhibitor, and metformin in healthy volunteers [abstract]. Clin Pharmacol Ther 2006;81(Suppl 1):S110
   Google Scholar
• Ayalasomayajula S, Tchaloyan S, Yeh CM. et al. A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with allopurinol, celecoxib and cimetidine in healthy subjects. Curr Med Res Opin 2008;24:717–2629Ayalasomayajula S, Tchaloyan S, Yeh CM. et al. A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with allopurinol, celecoxib and cimetidine in healthy subjects. Curr Med Res Opin 2008;24:717–26
   PubMed Web of Science ®Google Scholar
• Vaidyanathan S, Camenisch G, Schuetz H. et al. Pharmacokinetics of the oral direct renin inhibitor aliskiren in combination with digoxin, atovastatin and ketoconazole in healthy subjects: the role of P-glycoprotein in the disposition of aliskiren. J Clin Pharmacol. In Press. 30Vaidyanathan S, Camenisch G, Schuetz H. et al. Pharmacokinetics of the oral direct renin inhibitor aliskiren in combination with digoxin, atovastatin and ketoconazole in healthy subjects: the role of P-glycoprotein in the disposition of aliskiren. J Clin Pharmacol. In Press.
   Google Scholar
• Dieterle W, Corynen S, Mann J. Effect of the oral renin inhibitor aliskiren on the pharmacokinetics and pharmacodynamics of a single dose of warfarin in healthy subjects. Br J Clin Pharmacol 2004;58:433–631Dieterle W, Corynen S, Mann J. Effect of the oral renin inhibitor aliskiren on the pharmacokinetics and pharmacodynamics of a single dose of warfarin in healthy subjects. Br J Clin Pharmacol 2004;58:433–6
   PubMed Web of Science ®Google Scholar
• Dieterle W, Corynen S, Vaidyanathan S. et al. Pharmacokinetic interactions of the oral renin inhibitor aliskiren with lovastatin, atenolol, celecoxib and cimetidine. Int J Clin Pharmacol Ther 2005;43:527–3532Dieterle W, Corynen S, Vaidyanathan S. et al. Pharmacokinetic interactions of the oral renin inhibitor aliskiren with lovastatin, atenolol, celecoxib and cimetidine. Int J Clin Pharmacol Ther 2005;43:527–35
   PubMed Web of Science ®Google Scholar
• Vaidyanathan S, Bigler H, Yeh C. et al. Pharmacokinetics of the oral direct renin inhibitor aliskiren alone and in combination with irbesartan in renal impairment. Clin Pharmacokinet 2007;46:661–7533Vaidyanathan S, Bigler H, Yeh C. et al. Pharmacokinetics of the oral direct renin inhibitor aliskiren alone and in combination with irbesartan in renal impairment. Clin Pharmacokinet 2007;46:661–75
   PubMed Web of Science ®Google Scholar
• Bindschedler M, Degen P, Flesch G. et al. Pharmacokinetic and pharmacodynamic interaction of single oral doses of valsartan and furosemide. Eur J Clin Pharmacol 1997;52:371–834Bindschedler M, Degen P, Flesch G. et al. Pharmacokinetic and pharmacodynamic interaction of single oral doses of valsartan and furosemide. Eur J Clin Pharmacol 1997;52:371–8
   PubMed Web of Science ®Google Scholar
• Viazzi F, Leoncini G, Ratto E. et al. Mild hyperuricemia and subclinical renal damage in untreated primary hypertension. Am J Hypertens 2007;20:1276–8235Viazzi F, Leoncini G, Ratto E. et al. Mild hyperuricemia and subclinical renal damage in untreated primary hypertension. Am J Hypertens 2007;20:1276–82
   PubMed Web of Science ®Google Scholar
• Vaidyanathan S, Jin Y, Schiller H. et al. Aliskiren, a novel oral renin inhibitor, has no interaction with cytochrome P450 isoenzymes in vitro. Basic Clin Pharmacol Toxicol. In Press.36Vaidyanathan S, Jin Y, Schiller H. et al. Aliskiren, a novel oral renin inhibitor, has no interaction with cytochrome P450 isoenzymes in vitro. Basic Clin Pharmacol Toxicol. In Press.
   Google Scholar
• Azizi M, Webb R, Nussberger J. et al. Renin inhibition with aliskiren: where are we now, and where are we going? J Hypertens. 2006;24:243–5637Azizi M, Webb R, Nussberger J. et al. Renin inhibition with aliskiren: where are we now, and where are we going? J Hypertens. 2006;24:243–56
   PubMed Web of Science ®Google Scholar
• Barnett AH, Bain SC, Bouter P. et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004;351:1952–6138Barnett AH, Bain SC, Bouter P. et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004;351:1952–61
   PubMed Web of Science ®Google Scholar
• Parving HH, Persson F, Lewis JB. et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008;358:2433–4639Parving HH, Persson F, Lewis JB. et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008;358:2433–46
   PubMed Web of Science ®Google Scholar
• Zhao C, Vaidyanathan S, Yeh C-M, et al. Aliskiren exhibits similar pharmacokinetics in healthy volunteers and patients with type 2 diabetes mellitus. Clin Pharmacokinet 2006; 45:1125–3440Zhao C, Vaidyanathan S, Yeh C-M, et al. Aliskiren exhibits similar pharmacokinetics in healthy volunteers and patients with type 2 diabetes mellitus. Clin Pharmacokinet 2006; 45:1125–34
   PubMed Web of Science ®Google Scholar
• Verdecchia P, Calvo C, Mockel V. et al. Safety and efficacy of the oral direct renin inhibitor aliskiren in elderly patients with hypertension. Blood Press 2007;16:381–9141Verdecchia P, Calvo C, Mockel V. et al. Safety and efficacy of the oral direct renin inhibitor aliskiren in elderly patients with hypertension. Blood Press 2007;16:381–91
   PubMed Web of Science ®Google Scholar
• Fisher ND, Hollenberg NK. Unprecedented renal responses to direct blockade of the renin-angiotensin-system with aliskiren, a novel renin inhibitor. Presented at: American Heart Association Scientific Sessions; November 3-7, 2007; Orlando, FL.42Fisher ND, Hollenberg NK. Unprecedented renal responses to direct blockade of the renin-angiotensin-system with aliskiren, a novel renin inhibitor. Presented at: American Heart Association Scientific Sessions; November 3-7, 2007; Orlando, FL.
   Google Scholar
• Vaidyanathan S, Warren V, Yeh C. et al. Pharmacokinetics, safety, and tolerability of the oral renin inhibitor aliskiren in patients with hepatic impairment. J Clin Pharmacol 2007; 47:192–20043Vaidyanathan S, Warren V, Yeh C. et al. Pharmacokinetics, safety, and tolerability of the oral renin inhibitor aliskiren in patients with hepatic impairment. J Clin Pharmacol 2007; 47:192–200
   PubMed Web of Science ®Google Scholar